S&P 500   3,299.74 (+0.87%)
DOW   26,685.27 (+0.97%)
QQQ   269.01 (+1.21%)
AAPL   435.66 (+2.50%)
MSFT   214.64 (+4.70%)
FB   252.96 (-0.28%)
GOOGL   1,477.45 (-0.71%)
AMZN   3,115.98 (-1.54%)
NVDA   442.19 (+4.15%)
CGC   18.74 (+2.52%)
BABA   257.37 (+2.53%)
TSLA   1,494.06 (+4.42%)
MU   50.44 (+0.76%)
GE   6.18 (+1.81%)
AMD   77.88 (+0.58%)
T   29.52 (-0.20%)
F   6.68 (+1.06%)
ACB   10.26 (+0.69%)
GILD   71.76 (+3.21%)
NFLX   501.62 (+2.61%)
DIS   116.30 (-0.55%)
BAC   25.11 (+0.92%)
BA   162.30 (+2.72%)
S&P 500   3,299.74 (+0.87%)
DOW   26,685.27 (+0.97%)
QQQ   269.01 (+1.21%)
AAPL   435.66 (+2.50%)
MSFT   214.64 (+4.70%)
FB   252.96 (-0.28%)
GOOGL   1,477.45 (-0.71%)
AMZN   3,115.98 (-1.54%)
NVDA   442.19 (+4.15%)
CGC   18.74 (+2.52%)
BABA   257.37 (+2.53%)
TSLA   1,494.06 (+4.42%)
MU   50.44 (+0.76%)
GE   6.18 (+1.81%)
AMD   77.88 (+0.58%)
T   29.52 (-0.20%)
F   6.68 (+1.06%)
ACB   10.26 (+0.69%)
GILD   71.76 (+3.21%)
NFLX   501.62 (+2.61%)
DIS   116.30 (-0.55%)
BAC   25.11 (+0.92%)
BA   162.30 (+2.72%)
S&P 500   3,299.74 (+0.87%)
DOW   26,685.27 (+0.97%)
QQQ   269.01 (+1.21%)
AAPL   435.66 (+2.50%)
MSFT   214.64 (+4.70%)
FB   252.96 (-0.28%)
GOOGL   1,477.45 (-0.71%)
AMZN   3,115.98 (-1.54%)
NVDA   442.19 (+4.15%)
CGC   18.74 (+2.52%)
BABA   257.37 (+2.53%)
TSLA   1,494.06 (+4.42%)
MU   50.44 (+0.76%)
GE   6.18 (+1.81%)
AMD   77.88 (+0.58%)
T   29.52 (-0.20%)
F   6.68 (+1.06%)
ACB   10.26 (+0.69%)
GILD   71.76 (+3.21%)
NFLX   501.62 (+2.61%)
DIS   116.30 (-0.55%)
BAC   25.11 (+0.92%)
BA   162.30 (+2.72%)
S&P 500   3,299.74 (+0.87%)
DOW   26,685.27 (+0.97%)
QQQ   269.01 (+1.21%)
AAPL   435.66 (+2.50%)
MSFT   214.64 (+4.70%)
FB   252.96 (-0.28%)
GOOGL   1,477.45 (-0.71%)
AMZN   3,115.98 (-1.54%)
NVDA   442.19 (+4.15%)
CGC   18.74 (+2.52%)
BABA   257.37 (+2.53%)
TSLA   1,494.06 (+4.42%)
MU   50.44 (+0.76%)
GE   6.18 (+1.81%)
AMD   77.88 (+0.58%)
T   29.52 (-0.20%)
F   6.68 (+1.06%)
ACB   10.26 (+0.69%)
GILD   71.76 (+3.21%)
NFLX   501.62 (+2.61%)
DIS   116.30 (-0.55%)
BAC   25.11 (+0.92%)
BA   162.30 (+2.72%)
Log in

NASDAQ:CLDXCelldex Therapeutics Stock Price, Forecast & News

$11.04
+0.75 (+7.29 %)
(As of 08/3/2020 02:22 PM ET)
Add
Compare
Today's Range
$10.35
Now: $11.04
$11.19
50-Day Range
$2.99
MA: $11.05
$13.41
52-Week Range
$1.50
Now: $11.04
$13.91
Volume19,353 shs
Average Volume723,166 shs
Market Capitalization$249.06 million
P/E RatioN/A
Dividend YieldN/A
Beta3.31
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Read More
Celldex Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.92 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLDX
CUSIP15117B10
Phone908-200-7500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.57 million
Book Value$5.83 per share

Profitability

Net Income$-50,880,000.00
Net Margins-948.81%

Miscellaneous

Employees133
Market Cap$249.06 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable
$11.04
+0.75 (+7.29 %)
(As of 08/3/2020 02:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLDX News and Ratings via Email

Sign-up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

How has Celldex Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLDX stock has increased by 443.8% and is now trading at $11.04.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Celldex Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Celldex Therapeutics
.

When is Celldex Therapeutics' next earnings date?

Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Celldex Therapeutics
.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.02. The biopharmaceutical company earned $2.73 million during the quarter, compared to the consensus estimate of $1.28 million. Celldex Therapeutics had a negative net margin of 948.81% and a negative return on equity of 47.60%.
View Celldex Therapeutics' earnings history
.

When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work?

Shares of Celldex Therapeutics reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CLDX?

2 brokers have issued 1-year price objectives for Celldex Therapeutics' stock. Their forecasts range from $16.00 to $18.00. On average, they anticipate Celldex Therapeutics' stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 54.0% from the stock's current price.
View analysts' price targets for Celldex Therapeutics
.

Has Celldex Therapeutics been receiving favorable news coverage?

Media stories about CLDX stock have trended negative on Monday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Celldex Therapeutics earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
View the latest news about Celldex Therapeutics
.

Who are some of Celldex Therapeutics' key competitors?

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include Opko Health (OPK), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP), ACADIA Pharmaceuticals (ACAD), Precigen (PGEN), Micron Technology (MU), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), bluebird bio (BLUE) and Exelixis (EXEL).

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the following people:
  • Anthony S. Marucci, President, Chief Executive Officer & Director
  • Sam Martin, CFO, Secretary, Treasurer & Senior Vice President
  • Tibor Keler, Chief Scientific Officer & Executive VP
  • Elizabeth Crowley, Chief Product Development Officer & Senior VP
  • Ronald A. Pepin, Chief Business Officer & Senior Vice President

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include TSP Capital Management Group LLC (1.63%), Creative Planning (0.16%) and Raymond James Financial Services Advisors Inc. (0.07%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin and Tibor Keler.
View institutional ownership trends for Celldex Therapeutics
.

Which major investors are selling Celldex Therapeutics stock?

CLDX stock was sold by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Celldex Therapeutics
.

Which major investors are buying Celldex Therapeutics stock?

CLDX stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin, and Tibor Keler.
View insider buying and selling activity for Celldex Therapeutics
.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $11.04.

How big of a company is Celldex Therapeutics?

Celldex Therapeutics has a market capitalization of $249.06 million and generates $3.57 million in revenue each year. The biopharmaceutical company earns $-50,880,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis. Celldex Therapeutics employs 133 workers across the globe.

What is Celldex Therapeutics' official website?

The official website for Celldex Therapeutics is www.celldex.com.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.